Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10742MR)

This product GTTS-WQ10742MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10742MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2416MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ15440MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ15498MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ12621MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ402MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ13100MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ13337MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ14105MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW